Shares of XBiotech Inc. (NASDAQ:XBIT - Get Free Report) passed below its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $3.19 and traded as low as $2.90. XBiotech shares last traded at $2.97, with a volume of 37,863 shares traded.
XBiotech Price Performance
The stock's 50 day moving average is $3.17 and its two-hundred day moving average is $4.73. The stock has a market capitalization of $88.72 million, a PE ratio of -2.69 and a beta of 1.28.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Tuesday, March 18th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter.
Institutional Trading of XBiotech
Large investors have recently made changes to their positions in the company. Barclays PLC increased its stake in XBiotech by 13.9% in the fourth quarter. Barclays PLC now owns 30,004 shares of the biopharmaceutical company's stock valued at $119,000 after purchasing an additional 3,661 shares during the last quarter. Bank of America Corp DE increased its stake in XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after purchasing an additional 5,887 shares during the last quarter. JPMorgan Chase & Co. increased its stake in XBiotech by 68.2% in the fourth quarter. JPMorgan Chase & Co. now owns 14,624 shares of the biopharmaceutical company's stock valued at $58,000 after purchasing an additional 5,930 shares during the last quarter. Bank of New York Mellon Corp increased its stake in XBiotech by 7.5% in the fourth quarter. Bank of New York Mellon Corp now owns 91,060 shares of the biopharmaceutical company's stock valued at $360,000 after purchasing an additional 6,328 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in XBiotech in the third quarter valued at approximately $86,000. 55.70% of the stock is currently owned by hedge funds and other institutional investors.
About XBiotech
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Read More
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
